EMG
DRNA

Ellington Management Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Ellington Management Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,900
Closed -$160K – 850
2019
Q1 		$160K Buy
+10,900
New +$125K 0.03% 496

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ellington Management Group's DRNA Position: Q2 2019 in Review

Ellington Management Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2019, closing a stake of 10,900 shares — an estimated $160K sold.

Ellington Management Group first reported a position in DRNA in Q1 2019 and held it in 1 quarter. The position peaked at $160K in Q1 2019. 98 funds tracked by Wall St. Rank hold DRNA as of Q2 2019.

  • Ellington Management Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Ellington Management Group sold 10,900 Dicerna Pharmaceuticals, Inc. shares in Q2 2019, an estimated $160K.
  • Ellington Management Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Ellington Management Group's Dicerna Pharmaceuticals, Inc. position peaked at $160K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.